New Patent Promises to Accelerate Cancer Trials - Moffitt (computerized system patent)

New Patent Promises to Accelerate Cancer Trials:
"A new patent has been issued to Moffitt Cancer Center for a computerized system that efficiently selects the right patient for the right clinical trial. The newly patented system matches the registered patient's own molecular profile - warehoused in a database of thousands of patient-donated biological tissue or tumor samples - to the molecular design of the drug aimed at targeting their disease at the molecular level, and does it quickly....".

abstract: How valid are claims for synergy in published clinical studies?

Abstract

Background: Clinical trials evaluating drug combinations are often stimulated by claims of synergistic interactions in preclinical models. Overuse or misuse of the term synergy could lead to poorly designed clinical studies.

Conclusions: Synergy is cited frequently in phase I and phase II studies to justify the evaluation of a specific drug combination. Inappropriate methods for evaluation of synergy and poor assessment of therapeutic index have been used in most preclinical articles.

media: Henry Ford 1st in U.S. to Start Trial for Aggressive Brain Tumors - high-grade glioma (HGG)

Patients and referring physicians can call 313-916-8961 for further information.